Atea Pharmaceuticals director sells 22,619 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Atea Pharmaceuticals, Inc. director Bruno Lucidi exercised options to acquire 21,628 shares on November 17, 2026 at an exercise price of $1.24 per share, then sold 6,741 shares at a weighted-average price of $4.0335. On November 19, 2026, he exercised options to acquire 53,372 shares at $1.24 per share and sold 22,619 shares at a weighted-average $3.9445. The sales were reported as paying option exercise costs and serving tax-planning purposes; no Rule 10b5-1 plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F3 | 53,372 | $0.00 | $0.00 |
| Exercise | Common Stock | 53,372 | $1.24 | $66K |
| Sale | Common Stock F2 | 22,619 | $3.9445 | $89K |
| Exercise | Stock Option (Right to Buy) F3 | 21,628 | $0.00 | $0.00 |
| Exercise | Common Stock | 21,628 | $1.24 | $27K |
| Sale | Common Stock F1 | 6,741 | $4.0335 | $27K |
Footnotes (3)
- F1. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.00 to $4.10. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.91 to $3.97. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The option is fully vested and exercisable.
Key Figures
Key Terms
weighted average price financial
exercise price financial
fully vested and exercisable financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Atea Pharmaceuticals director Bruno Lucidi report for November 17, 2026?
What did Atea Pharmaceuticals director Bruno Lucidi report for November 19, 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.